MA53493A - Polypeptides leurres - Google Patents

Polypeptides leurres

Info

Publication number
MA53493A
MA53493A MA053493A MA53493A MA53493A MA 53493 A MA53493 A MA 53493A MA 053493 A MA053493 A MA 053493A MA 53493 A MA53493 A MA 53493A MA 53493 A MA53493 A MA 53493A
Authority
MA
Morocco
Prior art keywords
lures
polypeptides
polypeptides lures
Prior art date
Application number
MA053493A
Other languages
English (en)
Inventor
Jaume Pons
Bang Janet Sim
Original Assignee
Alx Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alx Oncology Inc filed Critical Alx Oncology Inc
Publication of MA53493A publication Critical patent/MA53493A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA053493A 2018-08-31 2019-08-29 Polypeptides leurres MA53493A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862725977P 2018-08-31 2018-08-31

Publications (1)

Publication Number Publication Date
MA53493A true MA53493A (fr) 2021-07-07

Family

ID=67997686

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053493A MA53493A (fr) 2018-08-31 2019-08-29 Polypeptides leurres

Country Status (5)

Country Link
US (1) US20210347848A1 (fr)
EP (1) EP3843772A2 (fr)
JP (1) JP2021534769A (fr)
MA (1) MA53493A (fr)
WO (1) WO2020047326A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019265019B2 (en) 2018-05-11 2025-11-06 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
CN114845710A (zh) * 2019-11-27 2022-08-02 Alx肿瘤生物技术公司 用于治疗癌症的组合疗法
JP2023528341A (ja) * 2020-06-01 2023-07-04 エーエルエックス オンコロジー インコーポレイテッド 低メチル化剤を含むがんを治療するための併用療法
US20220196651A1 (en) * 2020-12-06 2022-06-23 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
BR112023022774A2 (pt) 2021-05-13 2024-01-02 Alx Oncology Inc Terapias de combinação para tratamento de câncer
WO2025222106A1 (fr) * 2024-04-18 2025-10-23 Aktis Oncology, Inc. Miniprotéines leurres, compositions et procédés d'utilisation

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US20030118997A1 (en) * 2001-08-10 2003-06-26 Genset, S.A. Human cDNAs and proteins and uses thereof
US7074891B2 (en) * 2003-02-07 2006-07-11 Posco Leukocyte stimulating peptides
EP2455100A3 (fr) 2005-11-07 2012-11-07 The Rockefeller University Réactifs, procédés et systèmes pour la sélection d'un anticorps cytotoxique ou une variante de celui-ci
EP2815768A3 (fr) 2006-04-05 2015-01-14 The Rockefeller University Polypeptides présentant des propriétés anti-inflammatoires accrues et des propriétés cytotoxiques réduites et procédés afférents
RU2009140134A (ru) * 2007-04-23 2011-05-27 Вайет (Us) Способы и композиции для лечения и мониторинга лечения связанных с ил-13 нарушений
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
CN102257001A (zh) * 2008-12-19 2011-11-23 诺瓦提斯公司 治疗自体免疫和炎性病症的可溶性多肽
EP4311863A3 (fr) * 2009-05-15 2024-04-10 University Health Network Compositions et méthodes de traitement de cancers hématologiques ciblant l'interaction sirp alpha-cd47
SG194510A1 (en) * 2011-04-22 2013-12-30 Emergent Product Dev Seattle Prostate-specific membrane antigen binding proteins and related compositionsand methods
JP6460796B2 (ja) 2012-01-17 2019-01-30 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 高親和性ｓｉｒｐ−アルファ試薬
HRP20192013T1 (hr) * 2012-12-17 2020-02-07 Trillium Therapeutics Inc. Liječenje cd47+ oboljelih stanica sa sirp alfa-fc fuzijama
WO2016023040A1 (fr) 2014-08-08 2016-02-11 Alexo Therapeutics International Constructions de variant sirp-alpha et leurs utilisations
US9845345B2 (en) * 2015-05-18 2017-12-19 Ab Initio Biotherapeutics, Inc. SIRP polypeptide compositions and methods of use
BR102016018074A2 (pt) * 2015-08-07 2021-11-16 ALX Oncology Inc. Construção variante de sirp-alfa, seu método de preparação e seus usos, molécula de ácido nucleico, vetor, célula hospedeira, e composição farmacêutica
WO2017027422A1 (fr) 2015-08-07 2017-02-16 Alexo Therapeutics Inc. Constructions contenant un domaine sirp-alpha ou un variant de celui-ci
MA47111A (fr) * 2016-12-22 2019-10-30 Univ Wake Forest Health Sciences Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer
JP2022523543A (ja) * 2019-03-06 2022-04-25 ジエンス ヘンルイ メデイシンカンパニー リミテッド 二機能性融合タンパク質及びその医薬的使用

Also Published As

Publication number Publication date
WO2020047326A3 (fr) 2020-04-09
WO2020047326A2 (fr) 2020-03-05
EP3843772A2 (fr) 2021-07-07
JP2021534769A (ja) 2021-12-16
US20210347848A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
FIC20253006I1 (fi) Linvoseltamabi
EP3890716A4 (fr) Polythérapies
EP3801265B1 (fr) Débitmètre urinaire
EP3846674C0 (fr) Spéculum vaginal
LT3890488T (lt) Herbicidiniai deriniai
DK3810587T3 (da) Substituerede alkoxypyridinylindolsulfonamider
EP3802565A4 (fr) Polypeptides
EP3872558A4 (fr) Optoisolateur
DK3737402T5 (da) Modificeret protein
EP3904196A4 (fr) Navire
EP3878374A4 (fr) Dispositif d'occlusion
EP3721129C0 (fr) Cryosphère
EP3870698A4 (fr) Polypeptides anti-pathogènes
EP3844177A4 (fr) Polythérapies
DK3587968T3 (da) Fluidsystem
EP3773733A4 (fr) Métallo-liothyronine
DK3752258T3 (da) Trampolin
ES1207586Y (es) Furgo-caravana
EP3787995C0 (fr) Selle de harnachement
MA49925A (fr) Claie
DE112019000442A5 (de) Ringtilgereinrichtung
NO20181678A1 (no) Rissanviser
ES1214389Y (es) Plomo de pesca anti-enroque
JP1628556S (ja) たい焼
JP1628555S (ja) たい焼